{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007731426,0.0005240154,0.002049763,0.001386694,0.0002733714,0.002475634,0.001029233,0.001423733,0.003089272],"category_scores_gemma":[0.009206142,0.0002892748,0.001274899,0.001732673,0.001023209,0.003612124,0.0008361812,0.002415628,0.0005180879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001210429,"about_ca_system_score_gemma":0.002834428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001099278,"about_ca_topic_score_gemma":0.003029829,"domain_scores_codex":[0.9984352,0.0005450149,0.000327862,0.0001842026,0.0004379782,0.00006963662],"domain_scores_gemma":[0.990308,0.006644198,0.001294634,0.0001368217,0.001362019,0.000254372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000749919,0.00006389444,0.0008913946,0.04079111,0.0005095015,0.0001588545,0.0001650557,0.0004033007,0.0007147306,0.003974649,0.01320372,0.9383739],"study_design_scores_gemma":[0.0007270629,0.002125341,0.006714432,0.1118904,0.003881885,0.001642617,0.0009533985,0.0009171856,0.0008258651,0.01528856,0.8549328,0.0001004943],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002792042,0.9968768,0.00005214612,0.002326,0.0001648394,0.000003089038,0.00001434671,0.000003331041,0.0002801644],"genre_scores_gemma":[0.004869538,0.992243,0.0002219554,0.001838162,0.0006427403,0.000009268918,0.00002679044,0.000002558809,0.0001460377],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007731426,"threshold_uncertainty_score":0.04088813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02692938279819948,"score_gpt":0.4086304143515668,"score_spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}